NEURONAX is a biopharmaceutical company based in Clermont-Ferrand and Lyon (France).
Our vocation is to develop first-in-class innovative drugs to treat patients with traumatic or severe neurological disorders with high unmet medical needs. Our ambition is to improve the recovery of the functionality and the quality of life for patients.
Our lead product (NX210) is a very promising drug with a high potential in many neurological disorders. This is a peptide with multi-functional action and its efficacy is supported by several pre-clinical proof of concept studies. We observed in vivo its capacity to regrow the nerve fibers after traumatic spinal cord injuries and to support functional recovery. The properties of NX210, and its patented analogs, have driven us with a strong rational to investigate in neurological disorders as Multiple Sclerosis, Alzheimer, Parkinson,..
A Phase I clinical trial in patients with Spinal Cord Injury is now authorized by French and Belgian Health Authorities.